Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J v. Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Stent patent infringement verdict is set aside by Wilmington, Delaware federal court and a new trial will be held on the charge that Boston Scientific's NIR stent infringes a claim of a Johnson & Johnson patent. An initial damage award of $324.4 mil. to J&J was set aside in March (1"The Gray Sheet" April 1, 2002, In Brief). The judge also entered a "final judgement" that co-defendant Medtronic AVE's stents did not infringe the firm's patents "and stayed further proceedings in the [Boston Scientific] case until after any appeal of that judgment by J&J," Boston Scientific says. J&J plans to appeal...

You may also be interested in...



J&J v. Boston Scientific

Stent patent infringement award of $324.4 mil. to Johnson & Johnson is set aside and a new damages trial has been ordered in Wilmington federal court, Boston Scientific announces March 28. However, the court upheld a portion of a December 2000 jury verdict that found the NIR stent, made by Medinol for Boston Scientific, infringed one claim of J&J's '762 Palmaz balloon expandable stent patent (1"The Gray Sheet" Dec. 18, 2000, p. 16). "Regardless of the outcome of the new damages trial, we plan on appealing any infringement judgment entered," Boston Scientific says...

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel